The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies

Biotechnology products are being designed increasingly as multivalent, multifunctional structures based on recombinant fusion proteins. To augment the existing repertoires of such agents as produced by genetic engineering alone, we envisioned and developed the Dock-and-Lock (DNL) method, which enables site-specific conjugation of two modular components only with each other, producing a covalent construct of defined composition with retained bioactivity. The basic strategy of DNL involves the generation of two types of modules, one containing the dimerization and docking domain (DDD) of cAMP-dependent protein kinase A and the other containing the anchoring domain (AD) of an interactive A-kinase anchoring protein. Docking a DDD module with an AD module occurs spontaneously, and the resulting complex is locked with disulfide bonds to enhance in vivo stability. This new platform technology provides a versatile approach to create novel bispecific antibodies of multiple valencies, with potential applications in the detection and therapy of diverse diseases.

[1]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[2]  J. K. Hofmeister,et al.  Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.

[3]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[4]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[5]  J. Disselhorst,et al.  Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts , 2010, Molecular Cancer Therapeutics.

[6]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[7]  W. Mcbride,et al.  A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.

[8]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[9]  D. Burton,et al.  Square-Dancing Antibodies , 2007, Science.

[10]  W. Mcbride,et al.  Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma , 2009, Journal of Nuclear Medicine.

[11]  M. Polyak,et al.  CD20‐mediated apoptosis: signalling through lipid rafts , 2002, Immunology.

[12]  A. C. Cuello,et al.  Hybrid hybridomas and their use in immunohistochemistry , 1983, Nature.

[13]  D. Goldenberg,et al.  Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. , 2009, Blood.

[14]  N. Hollander.  Bispecific antibodies for cancer therapy. , 2009, Immunotherapy.

[15]  M. Juweid,et al.  Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. , 1995, Cancer research.

[16]  M. Bevan,et al.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Marvin,et al.  Recombinant approaches to IgG-like bispecific antibodies , 2005, Acta Pharmacologica Sinica.

[18]  J. Scott,et al.  A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes , 2001, The EMBO journal.

[19]  M. Polyak,et al.  Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. , 2002, Blood.

[20]  J. Weinstein,et al.  Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". , 1992, Cancer research.

[21]  W. McBride,et al.  Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Hendzel,et al.  The CD20 Calcium Channel Is Localized to Microvilli and Constitutively Associated with Membrane Rafts , 2004, Journal of Biological Chemistry.

[23]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.

[24]  R E Fulton,et al.  Bispecific and bifunctional single chain recombinant antibodies. , 2001, Biomolecular engineering.

[25]  J. Scott,et al.  Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract , 2005, FEBS letters.

[26]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[27]  B. Power,et al.  A new generation of protein display scaffolds for molecular recognition , 2006, Protein science : a publication of the Protein Society.

[28]  John D. Scott,et al.  AKAP signalling complexes: focal points in space and time , 2004, Nature Reviews Molecular Cell Biology.

[29]  J N Weinstein,et al.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Mcbride,et al.  A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. , 2008, Cancer research.

[31]  W. Mcbride,et al.  Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Fraser,et al.  Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. , 1991, The Journal of biological chemistry.

[33]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[34]  Chien-Hsing Chang,et al.  Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. , 2008, Blood.

[35]  D. Goldenberg,et al.  Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. , 2010, Blood.

[36]  W. Mcbride,et al.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. , 2010, Seminars in nuclear medicine.

[37]  F. Dahlquist,et al.  Signal transduction in bacteria: CheW forms a reversible complex with the protein kinase CheA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Parren,et al.  Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo , 2009, Nature Biotechnology.

[39]  Zhen-ping Zhu,et al.  Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. , 2007, Journal of immunological methods.

[40]  M. de Jong,et al.  Of Mice and Humans: Are They the Same?—Implications in Cancer Translational Research , 2010, Journal of Nuclear Medicine.

[41]  R. Rudolph,et al.  Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.

[42]  Naoto Hoshi,et al.  Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  John D. Scott,et al.  The molecular basis for protein kinase A anchoring revealed by solution NMR , 1998, Nature Structural Biology.

[44]  Stefan Kammerer,et al.  Designing isoform-specific peptide disruptors of protein kinase A localization , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[46]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[47]  R. Kontermann,et al.  Recombinant bispecific antibodies for cellular cancer immunotherapy. , 2007, Current opinion in molecular therapeutics.

[48]  D. Goldenberg,et al.  Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. , 2008, Cancer research.

[49]  P F Davison,et al.  Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. , 1985, Science.

[50]  M. Glennie,et al.  Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. , 1987, Journal of immunology.

[51]  G. Nakamura,et al.  Isolation and characterization of the B-cell marker CD20. , 2005, Biochemistry.

[52]  M. Unno,et al.  Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells* , 2007, Journal of Biological Chemistry.

[53]  M. Tarlov,et al.  Determination of protein aggregation with differential mobility analysis: Application to IgG antibody , 2008, Biotechnology and bioengineering.

[54]  S. Vallabhajosula,et al.  Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. , 2008, Radiology.

[55]  K. Fujimori,et al.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.

[56]  M. Colledge,et al.  AKAPs: from structure to function. , 1999, Trends in cell biology.

[57]  R. Sanyal,et al.  Cholesterol depletion inhibits src family kinase‐dependent calcium mobilization and apoptosis induced by rituximab crosslinking , 2005, Immunology.

[58]  Jianping Ding,et al.  Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab* , 2007, Journal of Biological Chemistry.

[59]  S. Morrison,et al.  Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.

[60]  Zhen-ping Zhu,et al.  Single Variable Domain-IgG Fusion , 2006, Journal of Biological Chemistry.

[61]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[62]  Yuni Fang,et al.  Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines , 2002, Cancer Immunology, Immunotherapy.

[63]  Chien-Hsing Chang,et al.  The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity , 2007, Clinical Cancer Research.

[64]  Andreas Plückthun,et al.  Engineered proteins as specific binding reagents. , 2005, Current opinion in biotechnology.